Circulating Tumour DNA as a Complementary Tool for Treatment Evaluation in HPV ‐Associated Head and Neck Squamous Cell Carcinoma: An Observational Cohort Study
Clinical Otolaryngology · 2025
DOI: 10.1111/coa.14317 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical Otolaryngology, 2025. Verfasst von Anna Oldaeus Almerén und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden. Hauptthemen laut MEDLINE: Papillomavirus Infections, Squamous Cell Carcinoma of Head and Neck, DNA, Viral, Circulating Tumor DNA. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Örebro University, Lions Clubs International Foundation, Nyckelfonden- Örebro University Hospital Research Foundation.
Abstract (Originalsprache)
Objectives
HPV‐positive oropharyngeal squamous cell carcinoma (OPSCC) and head and neck carcinoma of unknown primary (HNCUP) are increasing. Despite good prognosis, recurrence rates range from 10% to 25%. Surveillance with clinical controls and imaging is not always reliable. Circulating tumour human papillomavirus DNA (ctHPV‐DNA) has emerged as a potential biomarker for treatment evaluation and detection of recurrence. We aimed to investigate the correlation between ctHPV‐DNA in HPV+ OPSCC/HNCUP and radiologic tumour burden. Additionally, we sought to assess whether ctHPV‐DNA could serve as a tool in treatment evaluation.
Design
A prospective observational cohort study.
Setting
This multicenter study involved three otolaryngology units located in central Sweden. We utilised HPV genotype‐specific assays for droplet digital PCR (ddPCR) to detect ctHPV‐DNA in plasma at diagnosis and follow‐up. ctHPV‐DNA levels were correlated to radiological tumour burden and radiological response using the Kendall Rank correlation coefficient and the Kruskal–Wallis test.
Participants
Patients with HPV+ OPSCC/HNCUP undergoing definitive (chemo)radiotherapy and enrolled in the CIRCOS study.
Results
Out of 54 patients, 51 were eligible for analyses. At baseline, ctHPV‐DNA was detectable in 88%. A majority of patients with a favourable radiological evaluation according to RECIST had a corresponding undetectable ctHPV‐DNA at follow‐up. The levels of ctHPV‐DNA at baseline correlated with total tumour volume and nodal volume ( rτ = 0.39, p < 0.01, respectively rτ = 0.26, p < 0.01). Conclusion ctHPV‐DNA shows correlation with tumour burden. This study strengthens the role of ctHPV‐DNA as a promising biomarker for treatment evaluation in HPV‐related OPC/HNCUP. With further research on serial plasma sampling, ctHPV‐DNA could complement radiological treatment evaluation in HPV+ OPSCC/HNCUP. Trial Registration: NCT05904327 [ ClinicalTrials.gov ]
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
- Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
- Department of Otolaryngology, Sahlgrenska University Hospital, Gothenburg, Sweden.
- Department of Clinical Sciences Intervention and Technology, Division of Ear Nose and Throat Diseases, Karolinska Institutet, Stockholm, Sweden.
- Department of Head and Neck Surgery, Medical Unit Head Neck Lung and Skin Cancer, Karolinska University Hospital, Stockholm, Sweden.
- Department of Laboratory Medicine, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
ORCID-Profile: Anna Oldaeus Almerén, Max Waenerlund, Fredrik Landström, Mathias von Beckerath, Alvida Qvick, Jessica Carlsson, Gisela Helenius
Förderung
- Örebro University
- Lions Clubs International Foundation
- Nyckelfonden- Örebro University Hospital Research Foundation
- Regionala Forskningsrådet Uppsala/Örebro
- Region Örebro läns forskningskommitté
- Örebro Universitet
- Nyckelfonden
Zitieren
APA
Almerén, A. O., Waenerlund, M., Landström, F., von Beckerath, M., Qvick, A., Carlsson, J., & Helenius, G. (2025). Circulating Tumour DNA as a Complementary Tool for Treatment Evaluation in HPV ‐Associated Head and Neck Squamous Cell Carcinoma: An Observational Cohort Study. Clinical Otolaryngology. https://doi.org/10.1111/coa.14317
Vancouver
Almerén AO, Waenerlund M, Landström F, von Beckerath M, Qvick A, Carlsson J, et al. Circulating Tumour DNA as a Complementary Tool for Treatment Evaluation in HPV ‐Associated Head and Neck Squamous Cell Carcinoma: An Observational Cohort Study. Clinical Otolaryngology. 2025. doi:10.1111/coa.14317
BibTeX
@article{Almern2025,
author = {Almerén, Anna Oldaeus and Waenerlund, Max and Landström, Fredrik and von Beckerath, Mathias and Qvick, Alvida and Carlsson, Jessica and Helenius, Gisela},
title = {Circulating Tumour DNA as a Complementary Tool for Treatment Evaluation in HPV ‐Associated Head and Neck Squamous Cell Carcinoma: An Observational Cohort Study},
journal = {Clinical Otolaryngology},
year = {2025},
doi = {10.1111/coa.14317}
}
EUVIMED